The invention relates to a solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. The solid pharmaceutical preparation has an improved stability.

The invention relates to a microsphere composition comprising (a) a microsphere material; and (b) a lipidic liquid formulation comprising (i) an effective amount of a progestogen, and (ii) vitamin E or an analog of vitamin E, incorporated within said microsphere material, into said microspheres. The composition may be used to manage and control the synchronization of estrus in animals.

The present invention provides compositions for the treatment of phenylketonuria in mammals, as well as methods of preparing said compositions. The present invention also provides methods of treating phenylketonuria using the compositions of the invention.

A facility for industrial drying and/or encapsulation of thermolabile substances comprising at least one injection unit (1) wherein the thermolabile substance is introduced, an encapsulating material when the facility is used to encapsulate, a solvent, additives and an injection gas flow for obtaining droplets from the thermolabile substance. It further comprises a drying unit (2) through which the droplets and a drying gas are introduced for evaporating the solvent and comprises a collection unit (3) configured to separate the microcapsules generated from the drying gas and which is selected from a cartridge filter collector, a cyclone collector or a combination of the two. It also describes a method for the industrial encapsulation of thermolabile substances which is carried out at the proposed facility.

This invention provide novel compositions, methods and devices for sustained drug delivery. The compositions can include a fluid carrier; a plurality of first polymeric microparticles having a bioactive agent dispersed in the fluid carrier; and a plurality of second polymeric microparticles having a visualization agent dispersed in the fluid carrier with the first microparticles. Alternative compositions can include: a fluid carrier; and a plurality of polymeric microparticles having a bioactive agent encapsulated therein and a visualization agent on a surface of the polymeric microparticles, the plurality of polymeric microparticles being dispersed in the fluid carrier. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes at an amount of 1.0E-03 mL to 1.0E-16 mL per injection.

Disclosed herein are new cannabis compositions. In one embodiment, these new cannabis compositions are beverages, such as tea. In one embodiment, these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.

A method of treating or preventing endocarditis in a human patient in need of therapy is disclosed. The method comprises identifying a patient inflicted with or being at risk of contracting Staphylococcus aureus, Enterococcus faecalis, or Enterococcus faecium; and locally delivering to or in the vicinity of a heart valve a therapeutically or prophylactically effective amount of rifampicin, daptomycin, dalbavancin, vancomycin, or gentamycin, or a combination of rifampicin, daptomycin, dalbavancin, vancomycin, and gentamycin. The method comprises treatment or prevention of a bacterial biofilms on the endocardium caused by Staphylococcus aureus, Enterococcus faecalis, or Enterococcus faecium.

Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., ABRAXANE® nanoparticles) and antibodies. The compositions are used to effect hematologic cancer cell death.

The present invention relates to formulations and methods for stabilizing and protecting of biologic materials during harsh storing and use conditions, wherein the formulations relate to embedded bioactive materials and biologics, including live bacteria, in a protective glassy matrix.

Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., ABRAXANE® nanoparticles) and antibodies. The compositions are used to effect hematologic cancer cell death.